Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Current Deferred Revenue (2019 - 2025)

Apyx Medical (APYX) has disclosed Current Deferred Revenue for 4 consecutive years, with $2.0 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Current Deferred Revenue rose 17.65% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Dec 2024, up 17.65%, and an annual FY2024 reading of $2.0 million, up 17.65% over the prior year.
  • Current Deferred Revenue was $2.0 million for Q4 2024 at Apyx Medical, up from $1.7 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $2.0 million in Q4 2024 and bottomed at $600000.0 in Q4 2020.
  • Average Current Deferred Revenue over 3 years is $1.4 million, with a median of $1.7 million recorded in 2023.
  • The sharpest move saw Current Deferred Revenue surged 50.0% in 2020, then increased 17.65% in 2024.
  • Year by year, Current Deferred Revenue stood at $600000.0 in 2020, then soared by 183.33% to $1.7 million in 2023, then grew by 17.65% to $2.0 million in 2024.
  • Business Quant data shows Current Deferred Revenue for APYX at $2.0 million in Q4 2024, $1.7 million in Q4 2023, and $600000.0 in Q4 2020.